- Wondering whether Arcellx at around US$114.52 is pricing in too much optimism or still offers value? This article breaks down what the current valuation really reflects.
- The stock has returned 0.1% over the last 7 days, 67.2% over 30 days, 80.8% year to date and 63.9% over the past year, which naturally raises questions about how much of the long term 281.7% 3 year return is already in the price.
- Recent coverage around Arcellx has focused on its role within the biotech sector and how investors are reacting to its progress, with attention on how the company is positioned in a competitive space. That context is important for thinking about whether recent price strength reflects changing risk perceptions, expectations for its pipeline or a mix of both.
- Arcellx currently holds a 3 out of 6 valuation score, and the sections that follow will walk through what different valuation tools say about that, before finishing with a broader way to think about valuation that goes beyond the numbers alone.
Approach 1: Arcellx Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the entire business might be worth right now.
For Arcellx, the latest twelve month free cash flow is a loss of $213.7 million. Analysts provide free cash flow estimates out to 2030, with projections moving from losses in 2026 and 2027 into positive territory by 2028. The model used here is a 2 Stage Free Cash Flow to Equity approach, with analyst inputs for the earlier years, and Simply Wall St extrapolations extending those projections out to 2035. By 2030, projected free cash flow reaches $604.5 million.
After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of $487.83 per share. Compared with the recent share price of around $114.52, this implies Arcellx is 76.5% undervalued based on these assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Arcellx is undervalued by 76.5%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Approach 2: Arcellx Price vs Book
For profitable companies with meaningful assets on the balance sheet, the Price to Book, or P/B, ratio is a useful cross check on valuation because it compares what the market is paying to the accounting value of net assets.
In general, higher growth expectations or lower perceived risk can support a higher P/B multiple, while slower growth or higher risk usually point to a lower “normal” range. For Arcellx, the current P/B ratio is 16.70x. That sits well above the Biotechs industry average of 2.57x and below the peer group average of 43.23x.
Simply Wall St’s Fair Ratio metric goes a step further. It estimates what a more tailored P/B multiple might look like after considering factors such as earnings growth profile, industry, profit margins, market cap and company specific risks. This is often more informative than a simple comparison with peers or an industry average, which may not share the same risk and growth mix. In this case, no Fair Ratio is available for Arcellx, so it is not possible to quantify whether 16.70x points to under, over, or roughly fair pricing based on that model.
Result: ABOUT RIGHT
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Arcellx Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, which let you spell out your story for Arcellx, link that story to a forecast for revenue, earnings and margins, and then connect it all to a fair value that you can compare with today’s share price.
A Narrative is simply your view of what Arcellx could achieve and when, translated into numbers and a fair value estimate, instead of relying only on generic ratios or a single model output.
On Simply Wall St, Narratives sit inside the Community page. Millions of investors use them as an easy tool to see how their own fair value for Arcellx stacks up against the current market price, and to spot when their valuation is moving closer to, or further away from, that price.
Because Narratives are refreshed when new information such as earnings updates or major news is added, your Arcellx view can stay current rather than fixed. For example, one investor might see Arcellx as attractive only at around US$110, while another might feel comfortable up to around US$150, based on different stories and assumptions about its future.
Do you think there's more to the story for Arcellx? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com